	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR
Total Revenue	512	617	713	853	1,017	1,200	1,055
Cost of Operating Revenue	188	179	286	332	388	472	436
Gross Profit	324	438	427	521	629	728	619
Gross Margin	63.2	71.0	59.9	61.1	61.9	60.7	58.6
Total Operating Expenses	318	315	489	562	639	745	758
Operating Profit	194	302	224	291	378	455	296
Operating Margin	37.9	49.0	31.4	34.1	37.2	37.9	28.1
Financing Income/(Expense) - Net	30	9	11	13	10	23	30
Profit before Taxes	214	313	238	322	413	495	345
Income Taxes	45	78	63	82	104	123	85
Profit after Tax	169	235	175	240	308	372	261
PAT Margin	33.0	38.1	24.5	28.1	30.3	31.0	24.7
EPS - Basic - ex Extraordinary Items	16.16	22.45	16.72	22.95	29.45	35.52	24.94
EPS - Diluted - ex Extraordinary Items	16.16	22.45	16.72	22.95	29.45	35.52	24.94
EBIT	194	302	224	291	378	455	296
EBITDA	215	330	274	345	432	509	371
EBITDA Margin	42.0	53.5	38.4	40.5	42.4	42.4	35.2

Balance Sheet

Abridged

Understanding Balance Sheet

Concord Biotech Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	AR	AR	AR	AR
Total Current Assets	539	607	633	728	896	1,135	1,250
Long-Term Investments	5	3	3	10	1	34	91
Property Plant & Equipment - Net	381	558	644	765	786	844	866
Total Non-Current Assets	402	575	680	786	804	899	985
Total Assets	941	1,183	1,313	1,514	1,701	2,034	2,235
Total Current Liabilities	115	106	155	192	142	184	169
Long Term Debt	38	58	32	6	2	1	1
Total Non-Current Liabilities	55	77	54	32	32	37	51
Total Liabilities	170	183	210	224	174	222	220
Total Shareholders' Equity	770	999	1,103	1,290	1,527	1,813	2,019
Minority Interest	-	-	-	-	-	-	-4
Total Equity	770	999	1,103	1,290	1,527	1,813	2,015
Total Liabilities & Equity	941	1,183	1,313	1,514	1,701	2,034	2,235

Cash Flow

Abridged

Understanding Cash Flow Statement

Concord Biotech Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	176.28	255.69	231.44	303.33	348.16	417.79	282.92
Working Capital - Increase/(Decrease)	-21.72	-88.76	-22.05	-52.29	-81.18	-170.76	-13.92
Net CF from Operating Activities	154.56	166.92	209.39	251.05	266.98	247.03	269.00
Capital Expenditures - Net	155.30	204.18	155.45	145.06	85.51	110.97	95.05
Net CF from Investing Activities	-112.78	-195.31	-115.93	-163.53	-157.38	-162.98	-145.12
Dividends Paid - Cash - Total	-	-	-	53.56	71.45	91.54	111.94
Debt - LT & ST - Issuance/(Retirement) - Total	37.42	36.83	-27.42	-26.78	-26.50	-6.75	-0.65
Net Cash Flow from Financing Activities	-43.13	31.12	-97.94	-84.68	-97.96	-98.28	-112.59
Free Cash Flow to Equity	36.68	-0.42	26.52	79.21	154.96	129.31	173.29
Free Operating CF net dividend	-0.91	-37.25	53.88	52.40	109.84	44.32	61.91
Free Operating CF	-0.91	-37.25	53.88	105.96	181.29	135.86	173.84

Business Segment Analysis

FY End:

Mar 26

Concord Biotech Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Bulk Drug business (100.0%)₹ 95.15 Cr

Revenue / Sales

Bulk Drug business (100.0%)₹ 1,054.89 Cr

Assets

Bulk Drug business (100.0%)₹ 2,234.73 Cr

Operating Income

Bulk Drug business (100.0%)₹ 296.42 Cr

Regional Segment Analysis

FY End:

Mar 26

Concord Biotech Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Within India (53.4%)₹ 563.79 CrOthers (36.3%)₹ 383.25 CrUSA (10.2%)₹ 108.03 Cr

Historical Segment Analysis

Track how Concord Biotech Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Bulk Drug business	155	204	156	145	86	111	95

Frequently Asked Questions

What is the revenue of Concord Biotech Ltd.?

The latest trailing twelve month revenue of Concord Biotech Ltd. is ₹ 1,054.89 Cr, reflecting a 1-year growth of -12.10% and a 3-year CAGR of 7.33%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Concord Biotech Ltd.?

The latest trailing twelve month net profit (PAT) of Concord Biotech Ltd. is ₹ 260.91 Cr, with a 3-year earnings CAGR of 2.59%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Concord Biotech Ltd.?

The trailing twelve month EBITDA of Concord Biotech Ltd. is approximately ₹ 292.94 Cr (based on an operating margin of 27.77%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Concord Biotech Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Concord Biotech Ltd. is 24.78. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Concord Biotech Ltd.?

The debt-to-equity ratio of Concord Biotech Ltd. stands at 0.00. The interest coverage ratio is 1,034.40x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Concord Biotech Ltd.?

The estimated book value per share of Concord Biotech Ltd. is 192.81 (derived from a P/B ratio of 6.97 and market price of ₹ 1,344.80), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Concord Biotech Ltd.?

The trailing twelve month operating cash flow of Concord Biotech Ltd. is ₹ 269.00 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Concord Biotech Ltd. report consolidated or standalone financials?

Concord Biotech Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.